CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Phase 1 Recruiting 27 enrolled Beijing GoBroad Hospital CARsgen Therapeutics Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)

Timeline

Start: 2025-02-20
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CT1190B	Cell therapy	—	—

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Summary

Timeline

Drugs

Indications